Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HFpEF treatment study with ivabradine, isosorbide mononitrate, spironolactone, and exercise training
ACTRN12610001087044Phase 4Completed
- Sponsor
- The University of Queensland
- Start
- Jun 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of ivabradine, isosorbide mononitrate and spironolactone in heart failure with preserved ejection fraction (HFpEF) and diastolic dysfunction, sponsored by The University of Queensland. Started Jun 2007; status: completed.
02
Drugs
ivabradineisosorbide mononitratespironolactone
03
Conditions
heart failure with preserved ejection fraction (HFpEF)diastolic dysfunction
Beyond the preview
Go deeper on ACTRN12610001087044.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12610001087044.